| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $411,191 | 6 | 100 |
| LU YANG | CEO | 0 | $0 | 1 | $132 | $-132 |
| Ye Xiaofeng | CFO | 0 | $0 | 2 | $164,635 | $-164,635 |
| Ji Ping | director | 0 | $0 | 3 | $246,425 | $-246,425 |
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This …
Over the last 12 months, insiders at Adlai Nortye Ltd. have bought $0 and sold $411,191 worth of Adlai Nortye Ltd. stock.
On average, over the past 5 years, insiders at Adlai Nortye Ltd. have bought $0 and sold $411,191 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,700 shares for transaction amount of $168,717 was made by RHODES THOMAS L (director) on 2004‑09‑27.
| 2026-09-30 | Sale | Ji Ping | director | 10,000 0.0188% | $15.99 | $159,900 | -31.53% | |
| 2026-09-29 | Sale | Ji Ping | director | 214 0.0004% | $15.77 | $3,375 | -29.52% | |
| 2026-09-22 | Sale | Ji Ping | director | 5,000 0.01% | $16.63 | $83,150 | -28.18% | |
| 2026-08-26 | Sale | Ye Xiaofeng | CFO | 5,667 0.0101% | $14.25 | $80,755 | -3.20% | |
| 2026-08-24 | Sale | Ye Xiaofeng | CFO | 6,000 0.0372% | $13.98 | $83,880 | +2.95% | |
| 2026-05-13 | Sale | LU YANG | CEO | 10 <0.0001% | $13.18 | $132 | -13.20% | |
| 2006-04-26 | Sale | BLATZ ROBERT G | President and COO | 750 0.029% | $26.95 | $20,213 | ||
| 2006-04-24 | Sale | BLATZ ROBERT G | President and COO | 500 0.0193% | $26.94 | $13,470 | ||
| 2006-04-21 | Sale | BLATZ ROBERT G | President and COO | 500 0.0194% | $27.02 | $13,510 | ||
| 2006-04-20 | Sale | BLATZ ROBERT G | President and COO | 500 0.0193% | $26.95 | $13,475 | ||
| 2006-04-19 | Sale | BLATZ ROBERT G | President and COO | 1,050 0.0408% | $27.05 | $28,405 | ||
| 2006-04-17 | Sale | BLATZ ROBERT G | President and COO | 250 0.0098% | $27.24 | $6,810 | ||
| 2006-04-13 | Sale | BLATZ ROBERT G | President and COO | 250 0.0098% | $27.23 | $6,807 | ||
| 2006-04-12 | Sale | BLATZ ROBERT G | President and COO | 500 0.0197% | $27.46 | $13,728 | ||
| 2006-04-11 | Sale | BLATZ ROBERT G | President and COO | 250 0.0099% | $27.45 | $6,863 | ||
| 2006-03-24 | Sale | BLATZ ROBERT G | President and COO | 800 0.0325% | $28.29 | $22,635 | ||
| 2006-03-23 | Sale | BLATZ ROBERT G | President and COO | 200 0.0081% | $28.31 | $5,662 | ||
| 2006-03-22 | Sale | BLATZ ROBERT G | President and COO | 250 0.0102% | $28.38 | $7,095 | ||
| 2006-03-20 | Sale | BLATZ ROBERT G | President and COO | 2,300 0.0939% | $28.44 | $65,415 | ||
| 2006-03-17 | Sale | BLATZ ROBERT G | President and COO | 2,500 0.1023% | $28.50 | $71,250 |
| Increased Positions | 3 | +42.86% | 54,015 | +330.29% |
| Decreased Positions | 3 | -42.86% | 14,466 | -88.46% |
| New Positions | 2 | New | 49,940 | New |
| Sold Out Positions | 2 | Sold Out | 11,253 | Sold Out |
| Total Postitions | 7 | 0% | 55,903 | +241.83% |
| Two Sigma Securities, Llc | $15.00 | 0.01% | 11,228 | -26,168 | -69.97% | 2025-09-30 |
| Ubs Group Ag | $6.00 | 0.01% | 4,291 | -1,021 | -19.22% | 2025-09-30 |
| Eversource Wealth Advisors, Llc | $1.00 | <0.01% | 719 | +719 | New | 2025-09-30 |
| Bessemer Group Inc | $0 | 0% | 91 | +91 | New | 2025-09-30 |
| Morgan Stanley | $0 | 0% | 25 | -40 | -61.54% | 2025-09-30 |
| Citadel Advisors Llc | $0 | 0% | 0 | -16,909 | Sold Out | 2025-09-30 |